Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

umeclidinium

- PMLiVE

AZ share buyback suspension prompts M&A speculation

Analysts query new CEO Pascal Soriot’s intention to preserve cash reserves

European approvals for J&J cancer treatments

EC passes new Dacogen indications and backs subcutaneous Velcade

- PMLiVE

AZ launches science blog LabTalk

Hopes new blog will build relationships with potential collaborators

- PMLiVE

Bayer gets US green light for colorectal cancer drug Stivarga

Follows FDA approval for Sanofi and Regeneron's Zaltrap in same indication

- PMLiVE

Developing drugs to conquer cancer

Future treatments for suppression of antitumour activity, metastatic melanoma and NSCLC were showcased at ASCO 2012 with some exciting results

Board member Engelbert Tjeenk Willink to leave Boehringer

Replaced by head of established markets Allan Hillgrove

- PMLiVE

Board member Engelbert Tjeenk Willink to leave Boehringer

Replaced by head of established markets Allan Hillgrove

Novartis drug effective in hard-to-treat psoriasis

Secukinumab to commence phase III trials

Novartis building

Novartis heart failure candidate clears phase III trial

Serelaxin proves effective in reducing all-cause mortality

Novartis building

CHMP backs trio of Novartis products

Including two diabetes drugs and one for non-cancerous kidney tumours

Novartis building

Novartis signs $665m option deal with Selexys

Would acquire biotech company and its sickle cell disease drug

- PMLiVE

This month in 1901: Birth of Charles Brenton Huggins

This month in pharma: September 1901, the birth of the man who linked hormones with cancer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links